151 related articles for article (PubMed ID: 33274515)
1. US Food and Drug Administration Office of Women's Health: Promoting Therapeutic Optimization in Women.
South EM; Zinn RL; Huang CJ; Vasisht KP
J Clin Pharmacol; 2020 Dec; 60 Suppl 2():S11-S17. PubMed ID: 33274515
[No Abstract] [Full Text] [Related]
2. Office of Women's Health, Food and Drug Administration: future directions for women's health.
Wood SF
J Am Med Womens Assoc (1972); 2001; 56(4):197-8. PubMed ID: 11759792
[TBL] [Abstract][Full Text] [Related]
3. The Food and Drug Administration Office of Women's Health: impact of science on regulatory policy.
Obias-Manno D; Scott PE; Kaczmarczyk J; Miller M; Pinnow E; Lee-Bishop L; Jones-London M; Chapman K; Kallgren D; Uhl K
J Womens Health (Larchmt); 2007; 16(6):807-17. PubMed ID: 17678451
[TBL] [Abstract][Full Text] [Related]
4. The new NIH and FDA medical research policies: targeting gender, promoting justice.
Baird KL
J Health Polit Policy Law; 1999 Jun; 24(3):531-65. PubMed ID: 10386326
[TBL] [Abstract][Full Text] [Related]
5. US Food and Drug Administration office of women's health: update.
Sheppard A
J Am Med Womens Assoc (1972); 1999; 54(2):97-8. PubMed ID: 10319599
[TBL] [Abstract][Full Text] [Related]
6. Working Together to Address Women's Health in Research and Drug Development: Summary of the 2017 Women's Health Congress Preconference Symposium.
Feuerstein IM; Jenkins MR; Kornstein SG; Lauer MS; Scott PE; Raju TNK; Johnson T; Devaney S; Lolic M; Henderson M; Clayton JA
J Womens Health (Larchmt); 2018 Oct; 27(10):1195-1203. PubMed ID: 30325292
[TBL] [Abstract][Full Text] [Related]
7. The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.
Elahi M; Eshera N; Bambata N; Barr H; Lyn-Cook B; Beitz J; Rios M; Taylor DR; Lightfoote M; Hanafi N; DeJager L; Wiesenfeld P; Scott PE; Fadiran EO; Henderson MB
J Womens Health (Larchmt); 2016 Mar; 25(3):222-34. PubMed ID: 26871618
[TBL] [Abstract][Full Text] [Related]
8. FDA lifts ban on women in early drug tests, will require companies to look for gender differences.
Cotton P
JAMA; 1993 Apr; 269(16):2067. PubMed ID: 8468748
[No Abstract] [Full Text] [Related]
9. Gender-based differences in the toxicity of pharmaceuticals--the Food and Drug Administration's perspective.
Miller MA
Int J Toxicol; 2001; 20(3):149-52. PubMed ID: 11488556
[TBL] [Abstract][Full Text] [Related]
10. News from the Society for Women's Health Research: FDA doing poor job of monitoring drugs for sex differences.
Greenberger P
J Womens Health Gend Based Med; 2001 Nov; 10(9):829-30. PubMed ID: 11747675
[No Abstract] [Full Text] [Related]
11. Making a 'sex-difference fact': Ambien dosing at the interface of policy, regulation, women's health, and biology.
Zhao H; DiMarco M; Ichikawa K; Boulicault M; Perret M; Jillson K; Fair A; DeJesus K; Richardson SS
Soc Stud Sci; 2023 Aug; 53(4):475-494. PubMed ID: 37148216
[TBL] [Abstract][Full Text] [Related]
12. Women's health issues.
Wentz AC
Adv Intern Med; 1995; 40():1-30. PubMed ID: 7747644
[No Abstract] [Full Text] [Related]
13. Women's health at the FDA: will it endure?
Merkatz RB
J Womens Health (Larchmt); 2007; 16(6):818-21. PubMed ID: 17678452
[No Abstract] [Full Text] [Related]
14. Evaluation of worldwide clinical trials by gender: An FDA perspective.
Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
[TBL] [Abstract][Full Text] [Related]
15. Does exclusion or inclusion better protect women?
Shultz MM
J Gend Specif Med; 1998; 1(2):18-22. PubMed ID: 11281007
[No Abstract] [Full Text] [Related]
16. There is no women's health crisis.
Satel SL
Public Interest; 1998; 130():21-33. PubMed ID: 11658109
[No Abstract] [Full Text] [Related]
17. Trials and tribulations: including women in cancer clinical research.
Tang C; Hamad N
Lancet Haematol; 2021 Jul; 8(7):e477-e478. PubMed ID: 34171277
[No Abstract] [Full Text] [Related]
18. The FDA and women's health.
J Am Med Womens Assoc (1972); 1998; 53(2):105-7. PubMed ID: 9595905
[No Abstract] [Full Text] [Related]
19. Improving women's health through modernization of our bioinformatics infrastructure.
Oliva A; Pinnow E; Levin R; Uhl K
Clin Pharmacol Ther; 2008 Jan; 83(1):192-5. PubMed ID: 17987048
[TBL] [Abstract][Full Text] [Related]
20. Historical background of changes in FDA policy on the study and evaluation of drugs in women.
Merkatz RB; Junod SW
Acad Med; 1994 Sep; 69(9):703-7. PubMed ID: 8074759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
